Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.
Following the announcement, Denali's management will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss Denali’s second quarter 2026 financial results and provide a general business update.
The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of Denali's website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.
Investor Contact:
Laura Hansen
hansen@dnli.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States